Biotechnology company MoonLake Immunotherapeutics announced that its innovative drug Sonelokimab achieved positive topline results in a Phase II clinical trial for axial spondyloarthritis.
Show original
The trial data showed that Sonelokimab demonstrated significant advantages in the primary efficacy endpoint, offering new hope for patients. At the same time, the company disclosed its financial report for 2025, with core financial indicators remaining robust and continued increases in R&D investment, providing funding support for subsequent clinical advancement. This achievement marks an important breakthrough for MoonLake in the field of immunotherapy.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
Trending news
MoreBiotechnology company Trinity Biotech plc announced that it has officially signed a $25 million Securities Purchase Agreement (SEPA) with an affiliate of its financing partner Yorkville Advisors Global.
Revolut is considering a new round of stock sales in the second half of this year to meet pre-IPO demand.
Crypto prices
More
Bitcoin
BTC
$66,531.03
+5.71%
Ethereum
ETH
$1,972.6
+8.67%
Tether USDt
USDT
$1.0000
+0.01%
XRP
XRP
$1.42
+7.26%
BNB
BNB
$614.07
+5.97%
USDC
USDC
$1.0000
-0.01%
Solana
SOL
$84.49
+10.69%
TRON
TRX
$0.2858
+1.99%
Dogecoin
DOGE
$0.09812
+8.19%
Bitcoin Cash
BCH
$508.41
+6.03%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now